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Abstract
Background: Xeroderma pigmentosum (XP) is a rare autosomal recessive progeroid syndrome. It has recently been shown
that the underlying DNA repair defect plays a central role in the aging process. In addition to skin symptoms, various
premature neurological abnormalities have been reported.
Methodology/Principal Findings: We present the clinical neurological phenotype in 14 XP patients (seven subtypes), in
seven of these patients together with conventional and multiparametric advanced MRI data to assess the macrostructural
and microstructural cerebral morphology in comparison to controls, including volumetric measurements, MR spectroscopy
(
1H MRS), and diffusion tensor imaging (DTI). Clinical hallmarks were spinocerebellar ataxia, pyramidal tract signs, and mild
cognitive deficits. DTI demonstrated significantly reduced WM directionality in all regions investigated, i.e. the thalamus, the
corticospinal tracts and the dorsal corpus callosum. Single patients showed a marked relative hippocampal volume
reduction, but the patients were not different from controls in the volumetric measurements of hippocampal and whole
brain volumes at group level. However,
1H MRS demonstrated that the hippocampal formation was metabolically altered.
Conclusions: Themost prominent feature was the white matteraffectation, as assessed by DTI, with volume and directionality
reductions of the fiber projections involving both the craniocaudal fibers and the interhemispheric connections. These
findings, although heterogeneous among the study sample, could be correlated with the clinico-neurological symptoms. The
imaging findings support the position that myelin structures degrade prematurely in the brain of XP patients.
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Introduction
Nucleotide excision repair (NER) is a mechanism removing
bulky, helix distorting DNA lesions [1]. Defects in NER have been
shown to play a role in cancer as well as aging, and recent
publications indicate that NER deficiencies lead to premature
aging through suppression of the somatotroph axis [2]. Deficien-
cies of NER lead to the progeroid syndrome xeroderma
pigmentosum (XP) [3]. XP is an autosomal recessive disease with
an incidence of 1 patient per 10
6 livebirths [4]. Clinically, it is
characterised by premature development of sun-sensitive, xerotic
skin, hypo- and hyperpigmentation, telangiectasia and a highly
increased skin cancer risk [5,6].
There are seven different subgroups of XP plus a variant. The
seven complementation groups are named according to the
correspondingly defective NER-protein (XP A–G) and the variant
shows a defect in the translesion-DNA polymerase eta. In addition
to dermatological symptoms, XP patients also show premature
development of neurological abnormalities. The first detailed
description of XP in combination with neurological abnormalities
dated from 1932 [7]. In the late 1960s, XP was described as the
first human neurodegenerative disease caused by inherited defects
in DNA repair mechanisms [8,9,10]. Most of the neurological
abnormalities were found in the XP-A complementation group –
the most common form in Japan – and to a lesser extent in XP-D
and XP-G. Reported neurological signs and symptoms were
progressive and included peripheral neuropathy, deafness, bulbar,
extrapyramidal, and cerebellar symptoms, corticospinal tract
abnormalities, and mental deterioration [5,10,11,12]. These XP-
A, XP-D, and XP-G patients established the existence of the ‘XP
neurological disease’ as a distinct clinical entity. To date, it is
accepted that up to 30% of all XP patients present with
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30926neurological abnormalities [5,13,14] although the phenotype
remains ill-defined and it is unclear precisely which factor
determines severity and onset of neurological symptoms. Child-
hood and early adult manifestations are known [10], and XP with
childhood onset is often associated with intellectual impairment at
different degrees and a delayed motor development. Thus, a
mixture of developmental aberrations and degenerative features
could be observed. In a recent longitudinal investigation in 16
Finnish XP patients, a spectrum of neurological signs and
symptoms was reported [15]. Based on this and the fact that
molecular defects in XP apparently influences mitotic and
postmitotic tissue, a detailed brain imaging evaluation of patients
with various XP forms with respect to the neurological
presentation seems to be essential. In the present study, we
describe the clinical neurological phenotype in a cohort of
German XP patients as confirmed by measurement of reduced
DNA repair (unscheduled DNA synthesis (UDS)). It has previously
been published that XP patients with neurological symptoms show
mostly white matter pathology but also gray matter pathology in
the hippocampus and striatum [15], but numbers were small in the
tested cohort. In order to identify the cerebral morphological
correlates, we investigated their brain structures by use of
advanced MRI including multi-parametric MRI applications such
as volumetry, proton MR spectroscopy (
1H MRS), and diffusion
tensor imaging (DTI). With respect to the a priori hypotheses, we
acquired
1H MRS data in the hippocampus and performed
hippocampal volumetry since we considered the hippocampus the
most promising region-of-interest (ROI) according to the above-
named previous report. For the probably more widespread white
matter alterations, we used an explorative approach by an initial
whole brain-based analysis to define the ROIs for further analysis.
Materials and Methods
2.1. Patients
Patients were recruited from the outpatient clinic of the
Department of Dermatology, University of Tu ¨bingen, Germany.
All study investigations were performed in the Department of
Neurology, University of Ulm. Patients or their caregivers/parents
gave informed consent to participate in the study which had been
approved by the local Ethics Committees of the Universities of
Ulm and Tu ¨bingen.
A detailed general and neurological examination was carried
out. Skin changes observed in the study patients did not differ from
the spectrum of dermatological symptoms previously published for
XP including photosensitivity, xerosis cutis, poikiloderma, telan-
giectasia, squamous and basal cell carcinoma as well as malignant
melanoma. Dermatological features will thus not be detailed in the
following.
The patient’s descriptions are focused on medical history and
symptoms related to potential nervous system abnormalities. In
case of clinical evidence for a peripheral neuropathy and the
patient’s consent to participate, it was confirmed by a neurophys-
iological investigation according to clinical standards including the
measurement of the nerve conduction velocity (NCV) and
electromyography (MultilinerH Evolution 1.63; Jaeger/Toennies,
Hoechberg, Germany).
2.2 Neuroimaging: MRI data acquisition and
postprocessing
The same MRI protocol was acquired in all patients using the
same 1.5 Tesla MR system (Magnetom SymphonyH, Siemens,
Erlangen, Germany), equipped with a standard headcoil. Con-
ventional MRI included routine sequences of T1 and T2-weighted
imaging; for a synopsis of the sequences and parameters cf.
Table 1. No gap was used in the acquisition of MRI slices. In
order to avoid movement artefacts during acquisition, a vacuum
mold adapted to the subjects’ heads was used, and the young
patients were calmed by presence of one of their parents in the
scanning room. Post acquisition, all data sets were thoroughly
checked for motion artefacts, and only those MRI data without
any motion artefacts were used.
In seven patients, MP-RAGE data for volumetry and
1H MRS
data with hippocampal volumes of interest (VOIs) were acquired
(i.e., patients No. 1, 3, 4, 8, 12, 13, 14). For the demographic data
and the clinical neurological presentation of these patients, please
refer to Tables 2 and 3. The remaining patients could not be
investigated by neuroimaging due to fear and restlessness. In six of
the patients who received MRI, an additional cerebellar VOI
could be investigated by
1H MRS (exception, case 12). DTI data
were acquired in five patients (patients No. 4, 8, 12, 13, 14). In
order to compare the data of all MRI studies to a normal data
base, a sample of seven healthy controls were investigated who
were pairwise age-matched (maximum difference, 64 years) and
gender-matched. (In the only juvenile patient of the MRI group,
i.e. patient 3 aged 12 years, the matched control was also exactly
12 years old.) The control subjects received the identical MRI
scanning protocol as the patients.
2.2.1
1H MRS. For single-voxel spectroscopy (SVS), three
T2-weighted MR image sequences, covering the whole brain,
were initially acquired in sagittal, axial and coronal orientations, in
order to identify the appropriate positioning of the volumes of
interest (VOI) within the left-hemispheric hippocampus and the
cerebellum. Then, a T1w sagittal volume-rendering magnetization
prepared rapid acquisition gradient echo sequence (MP-RAGE,
Table 1) was acquired. For each hemisphere, a 20 mm6
20 mm620 mm VOI in the hippocampal region and a second
VOI in the cerebellum were studied. The hippocampus was
chosen since it was reported as one area with most prominent
morphological changes in the imaging data by Anttinen et al. [15].
We had to limit the acquisition to one hemisphere due to total
MRI acquisition time which prevented us from scanning both
sides. We decided to use the left hippocampus as the left
hemisphere usually reflects the dominant one. The VOIs for
patient and control 2 who were 12 years old was acquired
identically even if the inclusion of more parahippocampal tissue
was possible since compensation by the pairwise comparison was
considered to be appropriate. A first spectrum to check the free
induction decay as a marker for shim quality was acquired. All
spectra were rejected if the FID did not reach the baseline within
0.3 ms. Proton MR spectra were obtained with a point resolved
spectroscopy localization sequence (PRESS) for each VOI (TE
30 ms, TR 2,000 ms, 128 averages, 1,024 data points, delta
frequency of 22.7 ppm, bandwidth 1,000 Hz, TA 4 minutes
23 seconds). Reference spectra were acquired for each VOI
without water suppression with a long TR of 10,000 ms using two
excitations. This spectrum was subsequently used for eddy current
correction and for absolute metabolite quantification by fully
automatic spectral fitting. The LCModelH software (http://s-
provencher.com/pages/lcmodel.shtml) was used to estimate the
absolute concentrations of N-acetyl aspartate (NAA), total creatine
(Cr) and choline (Cho)-containing substances as well as myo-
inositol (mI). LCModelH compares the observed spectrum with a
library of spectra from previously acquired model solutions of the
respective metabolites.
Due to variations in voxel composition, image segmentation of
the MP-RAGE dataset was performed using a fully automated
segmentation procedure within the SPM99 software (Wellcome
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http://www.fil.ion.ucl.ac.uk/spm/software/spm99/), since the
MATLAB-based software code of the dedicated ‘spec-vox’ tool
box was optimised to SPM99. With respect to individual
localization and inclination of the VOIs within the segmented
brain, an SPM-based software toolbox using MATLABH 6.5 (The
MathWorks, Natick, MA, USA) was applied to determine the
fractional content as a percentage of gray matter (GM), white
matter (WM) and cerebrospinal fluid (CSF) within the VOI. The
metabolite concentrations were corrected for CSF amounts and
partial volume effects, respectively. Here, the metabolite concen-
trations obtained by LCModelH were divided by the fractional
amount of brain tissue. Subsequently, the volume-corrected ratios
of NAA divided by Cr, mI, and the sum of Cr and Cho,
respectively, and finally the ratio of mI divided by Cr were
analysed. The comparison of the values of the metabolite ratios
between patients and controls consisted of a Wilcoxon test for non-
parametric statistical analysis.
2.2.2 Region-of-interest-based volumetry. Volumetric
measurements were applied to the MP-RAGE datasets by use of
the interactive software program MRreg (Epilepsy Imaging Group,
Dept. of Clinical and Experimental Epilepsy, Institute of
Neurology, UCL, London, UK; http://www.erg.ion.ucl.ac.uk/
MRreg.html) (Lemieux et al. 1998). For the complex task of
hippocampal tracing, each rater had received an intense training
instructed by an experienced rater in data of normal and
pathologically altered brains different from the ones used in this
study. The manual delineation of the hippocampus was performed
according to the protocol, as described by Giesel et al. [16],
separately for each hemisphere. Here, the hippocampal measures
were initiated three slices rostrally to the point of fusion of the
pedunculi cerebri and the pons. Caudally, outlining of the
hippocampal formation was terminated at the level where the
fornix and the hippocampus fuse. The volume of the hippocampus
in each slice (in-slice volume) was calculated by multiplying the
voxel number of each trace by the voxel volume and dividing this
value by the magnification factor. The total hippocampal volume
was calculated as the sum of all in-slice volumes. To obtain the
total brain volume, the brain structures were outlined and
volumetrically measured in every single slice separately, using
the semi-automatic threshold and region-growing tool of the
software program MRreg. In order to provide a correction for
individual brain size, the individual relative hippocampal volume
was then calculated by dividing the hippocampal volumes by the
total brain volumes. The raters were blind to the subject
characteristics. Reliability data was assessed by calculating an
intraclass correlation coefficient from repeated measurements
[17,18]. Patient and control groups were compared using the t-test
within the Statistical Package for the Social Sciences software
(SPSS, Version 12.0, Chicago, IL, USA).
2.2.3 Diffusion Tensor Imaging. DTI scanning protocols
are also listed in Table 1. Five scans were k-space-averaged online
by the scanner software. The complete postprocessing and
statistical analysis was performed by use of the DTI analysis
software Tensor Imaging and Fiber Tracking (TIFT) [19,20,21]. First,
for the correction of eddy current induced geometric distortions of
the echo-planar imaging based DTI data sets, the method
proposed by Shen et al. [22] was applied. Second, a spatial
Table 1. MRI protocol: both conventional MRI sequences (columns 1–4) and non-routine sequences (columns 5–6) are included.
sequence parameters T1w SE T2w TSE T2w FLAIR DWI MP-RAGE DTI
repetition time (TR) (ms) 456 3760 9000 3400 1740 8000
time to echo (TE) (ms) 12 98 130 97 3.42 93
inversion time (TI) (ms) – – 2400 – 880 –
field of view (FOV) (mm) 230 230 230 230 250 192
matrix 1926256 3586512 2026256 1286128 2566256 1286128
orientation sagittal axial coronar axial sagittal axial
No of slices (n) 19 19 19 19 192 (3D) 45
slice thickness (mm) 555512 . 2
T1/T2 w, T1/T2 weighted; SE, spin echo; TSE, turbo spin echo; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion weighted imaging; MP-RAGE, magnetization
prepared rapid acquisition gradient echo; DTI, diffusion tensor imaging. Note that
1H MRS acquisition parameters are listed separately in the text.
doi:10.1371/journal.pone.0030926.t001
Table 2. Complementation group, sex, nutritional status and ages at XP- or neurological symptom onset and at recent
investigation are given.
1234567891 0 1 1 1 2 1 3 1 4
X P c o m p l e m e n t a t i o n g r o u p AACCCCCCDDX P - D / T T D FVn a
age at XP onset [years] ,41 ,1 ,17 1 . 51 2 ,21 ,2 1 02 15
age at neurological manifestation [years] 23 ,32 - ,1- 3 2 0 5 - ,26 8 - 5
age at investigation [years] 23 16 12 23 7 36 5 20 5 27 10 68 38 23
s e x m m m fffm m m m f fm f
BMI [kg/m
2] 26.2 unk 18.2 20.1 unk 23.6 15.4 23.1 unk unk 12.9 18.7 30.2 unk
TTD, Trichothiodystrophy; na, not assigned; unk, unknown.
doi:10.1371/journal.pone.0030926.t002
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in Mu ¨ller et al. [19] was applied. The process requires manually
set landmarks according to the Montreal Neurological Institute
(MNI) stereotactic standard space [23] performing affine
transformation. Fractional anisotropy maps were calculated as
previously described [19]. Then, a total of four regions of interest
(ROIs) with radius 10 mm (10 analysis voxels, in total 4,169
voxels) were positioned in the thalamus (left and right), the upper
corticospinal tract (CST, left and right), the internal capsule (left
and right), and the dorsal corpus callosum. The ROI parameter
was chosen to be larger than the estimated size of the structure of
interest to be secure that the whole structure was covered. Second,
since FT is automatically stopped if FA values are ,0.2, it was
ensured that no low FA regions contributed to the FT and fibre
tracts which did not originate from the structure itself could be
easily identified and (if not automatically stopped) could be
removed. The placement of a ROI in the hippocampus was not
possible due to the well-known local eddy current distortion
adjacent to the petrous temporal bones. Then, averaged FA values
within each ROI were calculated according to [19]. For a
comprehensive analysis, fiber tracking (FT) was performed using
manually defined startpoints in the thalamus. The thalamic
startpoint was chosen since the thalamus was found to be
involved in the XP-associated neuropathological process, and
hippocampal ROIs could not be chosen due to the low FA values
in mesiotemporal areas in DTI data as described above. FT
methods were used as described in [21]. In order to quantify the
tractography results, the technique named tractwise fractional
anisotropy statistics (TFAS) [20] was applied. By this approach,
the fiber tracts that originated from an XP-patient data set were
used for a statistical comparison to the fiber tracts from the age-
and gender-matched control data set. The individual fiber tracts
were used for the selection of the voxels that contributed to the
following statistical comparison by Student’s t-test [20].
Results
We have conducted a systematic investigation in XP patients to
determine the occurrence and characteristics of nervous system
involvement. We investigated 14 patients with cytologically
determined distinct XP subtypes.
3.1 Clinical characteristics
Fourteen patients (6 females, 8 males) were investigated, the
mean age at evaluation for the whole group was 22.4616.2 years,
covering a range of 5–68 years). The XP complementation group,
the age at evaluation, the age when first XP-specific symptoms
were reported, age at onset of XP, the age at manifestation of
neurological abnormalities and the body mass indices are
summarized in Table 2. Most patients included in this study
were complementation group XP-C since they represent the
largest population of XP patients in Europe. Habitus and
neurological findings of all investigated patients are given in
Table 3, together with what is known to be associated according
to the literature. Hallmarks of the phenotype and the individual
development are summarised for each patient in the Text S1.
In summary, regardless of the XP complemention group and
the age at investigation, 10/14 patients (71.4%) showed neuro-
logical abnormalities (Table 3). Abnormalities of the general
habitus consisted of short stature related to the individual age in 5/
14, dysmorphia of the face in 4/14, and microcephalus in 2/14
patients. Slowed psychomotor development (childhood milestones,
learning disabilities) was observed in 4/14. At investigation, these
patients presented with mental retardation and intellectual
impairment, but obvious dementia was observed only in one
patient. Irrespective of the cognitive status, disinhibition phenom-
ena were observed in five patients. One frequent neurological
feature in our patient sample was an atactic syndrome of the lower
limbs in 9/14, in five of them with functional deficits on gait
function, but ataxia could not be assigned to a clear-cut cerebellar
or spinocerebellar syndrome in seven cases while there were three
patients with definite cerebellar dysfunction. In three patients,
combined pseudobulbar and cerebellar speech disturbances were
observed. Definite pyramidal tract signs were observed in 3/14.
Other abnormal neurological features included a peripheral
neuropathy in two patients, seizures and myoclonus in at least
one patient.
3.2 Conventional MRI data
The results of the evaluation of the conventional MRI data are
summarized in the Text S1. Only one finding is to be described in
detail: in Case 8 (XP-C), MRI showed multiple spatially
dissemininated hyperintense white matter lesions, some of which
presented with a perifocal edema, some also showed a marked
homogeneous enhancement of contrast medium, one lesion
additionally demonstrated an abnormal signal in DWI. In
summary, the imaging findings of the bihemispheric lesions with
dissemination in time were compatible with an inflammatory
process (Figure 1).
Figure 1. Case 8 (XP-C). Upper panel: T1-weighted conventional MRI
post contrast in axial and coronal view. The arrow highlights a left-
hemispheric contrast-enhanced lesion with perifocal edema within the
frontoparietal white matter. Lower panel: Additional lesion in the
temporal white matter presenting as a hyperintensity in coronal FLAIR
(left) and T2-weighted (right) scans, marked by arrow. (For details,
please cf. 3.2 Conventional MRI data.).
doi:10.1371/journal.pone.0030926.g001
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3.3.1
1H MRS. Compared with each matched control, the
NAA/Cr ratios and the NAA/(Cr+Cho) ratios were lower in 5 out
of 7 patients in the hippocampal VOI (exceptions, cases 1 and 2).
The NAA/mI ratios were lower in all patients, while the mI/Cr
ratios were higher in all patients except from case 13. In the
cerebellar VOI, the NAA/Cr ratios, the NAA/(Cr+Cho) ratios,
the NAA/mI ratios, and the mI/Cr ratios did not show a
consistent pattern of results, since the patients showed lower or
higher values in 3 out of 6 matched pair analyses each, in various
combinations.
The statistical comparison of the volume-corrected metabolite
ratios, i.e. NAA/Cr, NAA/mI, NAA/(Cr+Cho), and mI/Cr, by
the Wilcoxon test showed significant differences between patients
and controls for the hippocampal VOI, whereas no statistical
differences could be observed in the cerebellar VOI. The results
are summarized in Table 4. The values of the four ratios in the
hippocampal VOI as differences between patients and controls are
demonstrated in Figure 2.
3.3.2 Volumetric measurements. Table 5 summarizes the
volumetric findings. Neither a reduced global brain volume nor
regional hippocampal atrophy was observed at group level. The
absolute values for hippocampal volumes ranged between 3.22
and 5.57 cm
3 in the patient sample with one exception (patient 14,
aged 23 years, 0.94 cm
3), while the hippocampal absolute volumes
in the age-matched pairs control sample ranged between 3.53 and
5.39 cm
3 (compare Table 5). For the individual normalized
volumes of the matched pairs, please see Figure 3. Both for left
and for right hippocampus, the patients’ mean volumes were lower
than the controls’, with no significant asymmetry effect (left vs.
right hippocampal volumes, p=0.581 in patients and p=0.571 in
controls). The whole brain volumes (WBV) were 1,122.76
256.1 cm
3 in patients and 1,168.66105.0 cm
3 in controls
(p=0.677). The total hippocampal volumes, both as the absolute
value and corrected for brain size, were lower in the patients. This
finding has to be judged as a trend since it failed to reach statistical
significance (p=0.159 for relative volumes). Examination at the
single age-matched pair level showed that in all patients with a
relative hippocampal volume below the 95% quartile of the
controls (3.349) (pairs 3, 4 and 14; Figure 3, upper panel) had
clearly smaller relative hippocampal volumes than their corre-
sponding controls. Patients with relative hippocampal volumes
within the 95% quantiles of the controls showed no reduced
relative volumes in 3 of 4 cases compared to the controls (pairs 1,
10, 11 and 13 in Figure 3, upper panel). Except from pair 14, the
corresponding matched pair whole brain volumes differed only
marginally (Figure 3, lower panel).
3.3.3 Diffusion Tensor Imaging. In Table 6, the DTI
results (mean values of the groups patients and controls,
respectively) are presented for the four different ROIs (which are
demonstrated in Figure 4) with respect to number of voxels and
average FA. The voxels with FA-values.0.2, i.e. the number of
voxels with a high degree of directionality, was significantly lower
in the XP patients in all ROIs, with the most marked differences in
Figure 2. Results of
1H MRS analysis: Differences of the metabolite ratios for each age- and gender-matched pair (cases 1, 3–7 and
9). The given values are the ratios of the patients subtracted from those of the controls. Different metabolite ratios are marked by distinct symbols,
the rhomb (dark blue) refers to NAA/Cr, the square (turquoise) refers to NAA/mI, the triangle (orange) refers to mI/Cr, and the point (green) refers to
NAA/(Cr+Cho), respectively. [NAA=N-acetylaspartate; Cr=creatine; mI=myo-inositol; Cho=choline].
doi:10.1371/journal.pone.0030926.g002
Table 4. Level of significance of the Wilcoxon-test of the
volume-corrected metabolite ratios derived from the
hippocampal and the cerebellar volume-of-interest (VOI),
respectively.
VOI Metabolite ratios (volume-corrected)
NAA/Cr NAA/mI NAA/(Cr+Cho) mI/Cr
Hippocampus ,0.05 ,0.01 ,0.05 ,0.05
Cerebellum n.s. n.s. n.s. n.s.
NAA, N-acetylaspartate; Cr, creatine; mI, myo-inositol; Cho, choline. n.s., not
significant.
doi:10.1371/journal.pone.0030926.t004
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significantly lower in the patients, thus demonstrating a reduced
level of directedness within the ROIs. (The differences between
ROIs are due to the physiological neuroanatomical variability of
directionality in different areas of the brain.) In summary, all
selected areas were found to exhibit white matter fiber changes in
association with XP.
Figure 5 shows the FT results with starting points in the
thalamic region (as the area with the most prominent differences)
pairwise for XP patients and each corresponding control. The
tract projections mainly show a posterior to anterior direction. In
some patients, depending on severity of the disease, the analysis
showed a different tract behaviour in the thalamic region which
may be caused by a low signal to noise ratio when the directional
information gets lost. The quantitative TFAS analysis resulted in
significant differences (p,0.005) between the FA values of the
voxels determined by FT in patients and in controls for all the age-
and gender-matched pairs (Table 7).
Discussion
4.1 Summary
XP is the first progeroid syndrome in which defective DNA
damage repair mechanisms account for neurodegeneration and
early neural developmental disabilities [8]. In the past three
decades, neurological abnormalities involving both the central and
peripheral nervous system and including low intelligence,
spasticity, ataxia, areflexia and hearing loss were observed in the
XP complementation groups A, B, C, D, F and G [2,5,14,24,25].
Japanese XPA patients showed neurological abnormalities more
often than patients belonging to other XP complementation
groups [14]. The more severe the molecular XP defect is, the more
pronounced the severity of the neurological phenotype seems to
be, opening an approach for a prognostic assessment of XP
patients [26].
In a recent study on the natural course of XP in 16 Finnish
patients, Anttinen and colleagues [15] reported that the neuro-
logical symptoms probably start slowly at about the age of 2 and
manifest at the age of 4–5 years as cognitive and cerebellar signs,
then slowly progress and finally affect the whole nervous system.
However, since the cause of the neurological disease is still
unknown (it cannot be caused by the UV photoproducts because
UV radiation penetrates only into the skin), our understanding of
the origin of the XP-associated neurological abnormalities is still in
its infancy so that Anttinen et al. conclude that neurological
problems in XP should be the focus of future research [15].
Beyond pure morphological information on brain structures grosso
modo as available from conventional MRI or (even to a much lesser
degree) from CT, advanced MRI-based neuroimaging techniques
are able to provide quantitative macrostructural and even
microstructural assessment of the brain in vivo.
4.2 Clinical data
The spectrum of the clinical neurological abnormalities in the
complete cohort was – although in general agreement with it –
beyond the XP patients described in the literature: the most
common features were a mild to moderate ataxia, pronounced in
the lower limbs (N=8) and clinical signs or symptoms of
pyramidal tract involvement in terms of spasticity/spastic gait,
preventing only two patients from walking without assistance.
Other common neurological symptoms were unspecific cognitive
deficits and a reduced psychomotor development (N=4) and
abnormal behaviour (N=5). Four of the patients had not reached
the age of ten years so that an early affection of the CNS, including
the cerebellar system and the corticospinal tracts, could be
demonstrated in the cross-sectional design. None of these young
XP patients was able to take part in the neuroimaging study due to
fear and motor restlessness. From the clinical viewpoint, in most of
these patients a clear classification to a distinct cerebellar or
spinocerebellar syndrome was difficult. In the total group, a
definite cerebellar syndrome including dysmetria and intention
tremor were observed in two cases with XP-A and TTD/XP-D.
Dysarthrophonia in a total of four patients was clinically a mixture
of cerebellar and pseudobulbar speech in three patients.
Pseudobulbar speech, as a feature of pyramidal tract dysfunction,
was present in all patients with definite limb signs of pyramidal
tract abnormalities.
Most patients in our study were from complementation group
XP-C due to highest prevalence of this group in Europe. These
patients did show neurological symptoms (Table 3) correlating
with morphological analysis. This is in contrast to the study by
Anttinen and colleagues [15] where no neurological symptoms
were found in XP-C patients, perhaps due to young age. However,
also in their study, mild morphological changes were detected by
MRI and the authors hypothesize that oxidative damage may be
the reason for neurological changes. From our point of view, this
may be a possible explanation even though involvement of the
respective proteins has not been shown for all XP proteins.
Investigation of clinico-morphological correlations such as studies
by Anttinen et al. and us will provide the possibility to
systematically investigate the role of different repair proteins in
the development of neurodegenerative symptoms.
There was one young patient with XP-D/trichothiodystrophy
(TTD) overlap syndrome; due to different disease causing
mutations in the DNA repair genes XP-D and TTD, the genetic
background of the autosomal recessive TTD is heterogeneous
[27]. It is well-known that TTD patients per se show a
heterogeneous phenotype, including developmental and neuro-
logical abnormalities (besides cutaneous and endocrinological
symptoms), and the patient from our cohort showed severe
neurological deficits with cerebellar symptoms, spastic tetraparesis
and mental impairment, progressively starting at an age of 18
months. The XP-D gene product is required for nucleotide
Table 5. Results of volumetric analysis in XP patients and controls.
proportion of right hippocampal
to whole brain volume
[610
23]
proportion of left hippocampal
to whole brain volume
[610
23]
total hippocampal volume
[cm
3]
proportion of hippocampal to
whole brain volume
[610
23]
XP patients 1.60160.329 1.61660.546 3.75561.443 3.21760.867
controls 1.84460.219 1.93060.256 4.40060.571 3.77560.460
t-test P=0.130 P=0.194 P=0.239 P=0.159
doi:10.1371/journal.pone.0030926.t005
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factor TFIIH as well. Therefore, different mutations in the XP-D
gene may result in a variety of clinical manifestations, from pure
mild XP disease to a severe phenotype with premature and
infantile developmental disabilities and progressive neurological
deterioration [28].
Few Caucasian patients from the complementation group XP-F
are described in the literature since these are mostly of Japanese
origin. Most of them have exclusively dermatological abnormal-
ities so that XP-F was considered a mild form with late onset [29],
although there is one report about a young boy with XP-F and a
severe progeroid syndrome including mental retardation and
ataxia [2]. The patient of our group, in her late sixties, showed
only a mild axonal sensorimotor neuropathy with consequent
afferent ataxia. Regarding the estimated frequency of polyneu-
ropathies between 25 to 50/100000, it remains unknown whether
Figure 3. Results of the volumetric measurements: upper panel, relative bilateral hippocampal volumes for pairs of XP patients and
corresponding controls; lower panel, whole brain volumes (WBV) for pairs of XP patients and corresponding controls. The 95%
quantile of the controls’ hippocampal volumes are indicated as red lines.
doi:10.1371/journal.pone.0030926.g003
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common causes for polyneuropathy were excluded. Up to now,
the only XP groups associated with neuropathy were XP-A and
XP-G in which mixed axonal-demyelinating neuropathies were
described [10,12,32].
4.3 Neuroimaging data
Seven patients with XP (three XP-C, one XP-A, one XP-F, one
XP-V, one unassigned case) out of the 14 patients cohort received
multiparametric MRI in order to assess the cerebral morphology
in vivo at a macrostructural and microstructural level in
comparison to controls. We aimed to analyze both grey matter
structures with respect to volumes and metabolism by volumetric
and
1H MRS measures, respectively, and white matter micro-
structural organisation by DTI. The pattern both for GM and for
WM alterations was heterogeneous among the group. Given that
Anttinen et al. also described a variation of neuroimaging results in
patients with XP complementation groups A and C [15], our
cohort which consisted of even more complementation groups
allowed for even more clinico-morphological variation. For future
studies, these results may be of interest with respect to other
diseases of the central nervous system, in particular neurodegen-
erative diseases such as the dementias. Neurological symptoms and
neuroimaging may be aligned with those findings in XP (where the
genetic and molecular defects are known), possibly giving
indications which clinical symptom may be caused by defects in
DNA repair or oxidative stress and which not.
It could be shown that single patients show a marked
hippocampal and whole brain atrophy but most of the patients
investigated in this study were not different from controls at this
quantitatively assessed macroscopic level. However, it could be
demonstrated that the hippocampal formation, although not
prominently thinned, was metabolically altered with lowered
NAA-based ratios as a marker of neuronal integrity and increased
MI-based ratios which is used both as a glial marker and
particularly a product of the degradation of myelin. Remarkably,
the cerebellar VOI did not demonstrate metabolic changes neither
at group nor at subject level, although clinical cerebellar signs were
present in single patients. It might be concluded that the process of
regional degeneration initiates in the hippocampal formation
before the cerebellum. For that purpose, longitudinal
1H MRS
data would be necessary. Other regions could not be assessed with
Table 6. Results of the region-of-interest (ROI)-based analyses of five patients and five age- and gender-matched controls.
ROI MNI coordinates x/y/z
number of voxels
with FA.0.2 average FA significance level
thalamus patients (2)11/221/18 24266662 0.2260.04 voxel number: p,0.01
average FA: p,0.05
thalamus controls 31136169 0.2660.01
upper corticospinal tract patients (2)22/221/47 35836447 0.3660.07 voxel number: p,0.05
average FA: p,0.05
upper corticospinal tract controls 39156171 0.4360.04
internal capsule patients (2)23/221/15 33476307 0.3760.04 voxel number: p,0.001
average FA: p,0.001
internal capsule controls 38166190 0.4560.03
corpus callosum patients 0/235/20 23776519 0.2960.12 voxel number: p,0.05
average FA: p,0.05
corpus callosum controls 32376239 0.4460.06
FA values are given as mean 6 SD. Significance level was determined by Student’s t-test. Left- and right-hemispheric ROIs are arithmetically averaged for each
localisation (except from corpus callosum where only one ROI was selected) since there were no asymmetric findings in all of them. MNI, Montreal Neurological
Institute; FA, fractional anisotropy.
doi:10.1371/journal.pone.0030926.t006
Figure 4. Localization of the regions-of-interest (ROIs) for FA analysis of the DTI data, overlain onto a b=0 data set together with a
colour-coded FA-map (red, right-left direction; green, anterior-posterior direction; blue, craniocaudal direction). From left to right,
the bilateral thalamic ROIs are presented in an axial slice, the bilateral ROIs in the upper corticospinal tracts in a coronal slice, the bilateral ROIs in the
internal capsule in a coronal slice, and the ROI in the dorsal corpus callosum in a sagittal slice. MNI, Montreal Neurological Institute standard space.
doi:10.1371/journal.pone.0030926.g004
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VOIs due to technical prerequisites and the bilateral hippocampus
and the cerebellum were chosen as they were previously reported
as areas involved in the XP-related CNS affection.
The analysis of WM microstructure by use of DTI brought the
most striking results. The thalamus, the corticospinal tracts and the
dorsal corpus callosum were selected post acquisition for white
matter directionality analysis since pyramidal tract pathology
seemed to be obvious from the clinical phenotype. Unfortunately,
hippocampal and cerebellar WM tracts could not be assessed due
to the well-known local interferences in DTI data adjacent to the
petrous temporal bones and the limitations of the field of view.
The WM directionality was reduced in all areas in the XP patients,
irrespective of the complementation group. Of whatever etiology
the WM process is, it seems to be a generalised one since all WM
areas investigated were shown to be markedly altered with
thinning of fibertracts and no correlation with the clinical
presentation could be observed (e.g., pyramidal tract abnormalities
were not associated with pyramidal signs). Although DTI does not
differentiate between antero- and retrograde degeneration pro-
cesses, a primary WM process in association with XP is most
probable, given the lack of whole brain atrophy corresponding to
cortex structures. In addition, a finding in conventional MRI in
one XP-C patient was most remarkable, with multiple spatially
disseminated hyperintense lesions, partly with perifocal edema and
a marked homogeneous enhancement of contrast medium
(Figure 1), compatible with an inflammatory process with
dissemination in time and reminiscent of MRI findings in multiple
sclerosis. These lesions fulfilling imaging criteria of acute
inflammation have to be considered a by chance finding. It has
been reported that patients with XP show immunosuppression in
cellular immunity. Cells from XP patients can show abnormally
high rates of apoptosis after cellular stress such as ultraviolet
radiation [33]. It is tempting to speculate that high levels of
oxidative stress, i.e. cyclopurines [34], may induce apoptosis in
neurons which in turn can lead to cerebral inflammatory
reactions, similar to autoimmune disease, as observed in this
patient. However, this is speculative and this question can only be
investigated when neuronal cells from patients with DNA repair
deficiency syndromes are available. It might be worthwhile to
perform MRI scanning on a regular basis in XP to screen for
potential pathological processes and to correlate it with cerebro-
spinal fluid analysis. This finding is in favour of the latter position
within the current discussion whether the myelin structures did
form insufficiently during development or myelin structures
degrade prematurely in the brain in these patients [26].
Some limitations of our study need to be addressed. First, the
study sample is small and heterogeneous, due to the rareness of
XP. Methodologically, we thus were cautious in the interpretation
of the effects and limited most analyses to a comparison of
matched pairs. Second, there was a bias in that the more severe
affected patients, in particular with respect to cognitive and
neuropsychological abnormalities, could not be investigated by
MRI due to non-compliance and motion artifacts so that the
results observed in this study might be considered as even less
pronounced than they might be found in the clinically more
severely affected patients. As one example, patient 14 in this study
who presented with the most severe neurological phenotype of
those patients who received MRI showed the most prominent
results in the imaging analysis. Other limitations are caused by
methodological restrictions of the neuroimaging data acquisition:
for a complete multiparametric analysis of the ROIs, an SVS
Table 7. Results of the TFAS analysis of five patients and five
age- and gender-matched controls.
number of voxels
in the fiber tracts average FA
significance
level
patient no. 4 2831 0.3260.13 p,0.001
control no. 1 2556 0.3560.13
patient no. 8 2590 0.3060.13 p,0.001
control no. 2 2075 0.3360.12
patient no. 12 1496 0.2660.10 p,0.001
control no. 3 2046 0.3060.11
patient no. 13 1838 0.2660.09 p,0.001
control no. 4 2192 0.3060.11
patient no. 14 1868 0.2860.10 p,0.005
control no. 5 1764 0.2960.11
FA values are given as mean 6 SD. Significance level was determined by
Student’s t-test. FA, fractional anisotropy.
doi:10.1371/journal.pone.0030926.t007
Figure 5. DTI-based fiber tracking (FT) with starting points in the thalamus for the individual XP patients (upper panel) and the
age- and gender-matched controls (center panel). FT was additionally performed in an averaged data set obtained from the data sets of the
five controls (lower panel). Background is the individual b=0 data set.
doi:10.1371/journal.pone.0030926.g005
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corpus callosum would have been useful as well as a DTI-based
analysis of the hippocampi. The first could not be included since a
specific VOI placement was not done due to a different a priori
hypothesis, the latter could not be performed due to the well-
known local eddy current distortion adjacent to the petrous
temporal bones.
4.4 Conclusion
The primary defect in XP is the response to DNA damage.
Given that aging results from accumulated damage [2], that each
tissue has different requirements for the various repair mechanism
[35], and further that since reactive oxygen species play a central
role in generating aging-associated DNA damage, it appears
possible that endogenous damage caused by reactive oxygen
species, a consequence of the high rate of oxidative metabolism in
the brain, is the underlying cause of neuropathogenic DNA
lesions. DNA lesions induced by reactive oxygen species have the
potential to block transcription by RNA polymerase II, and their
accumulation in repair-defective individuals may cause neuronal
cell death, e.g. through apoptosis [36]. Many neurodegenerative
diseases caused by molecular defects in DNA repair are clinically
either ataxias or motor neuron degeneration followed by cognitive
decline and impairment of neurological systems. The correlation
between molecular defect and neuron-specific impact may provide
the missing link that allows us to begin to understand the
relationship between neurodegeneration and defective DNA
repair [9,37]. With regard to the present study, a vulnerability
pattern of this neurodegenerative process could be assessed in vivo
in the brains of XP patients which was observed across
complementation groups. The prominent neuroanatomical corre-
lates seem to be WM alterations involving both craniocaudal fibers
such as the pyramidal tracts and interhemispheric connections
such as the corpus callosum. Thus, WM affection could be
demonstrated to be prominent in association with XP, in contrast
to several reports of prominent GM alterations. In addition, the
hippocampus is a structure which could be shown to be reduced in
volume in single patients and to be pathologically altered in
metabolism at group level. In contrast, whole brain atrophy was
not a feature of XP in our sample, and cerebellar involvement –
although obvious in the clinical domain – could not be related to
neuroimaging findings.
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